<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055041</url>
  </required_header>
  <id_info>
    <org_study_id>Pharmacol no.03 /2008 Research</org_study_id>
    <nct_id>NCT01055041</nct_id>
  </id_info>
  <brief_title>Controller Medications in the Management of Bronchial Asthma</brief_title>
  <official_title>A Randomized, Open Labeled Comparative Study to Assess the Efficacy and Safety of Controller Medications as Add on to Inhaled Steroid and Long Acting β2 Agonist in Treatment of Moderate to Severe Persistent Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Government Medical College, Bhavnagar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Government Medical College, Bhavnagar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to know the effect of another controller medication add on to
      the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and
      compliance in patients of moderate to severe persistent bronchial asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome was percentage of improvement in FEV1</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in PEFR (Peak expiratory flow rate), ACQ scores(asthma control questionnaire score), rates of adverse drug reaction and EPACs (episodes of poor asthma control)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Moderate to Severe Persistent Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>inhaled budesonide and formeterol plus oral montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhaled budesonide and formeterol plus oral doxophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doubling the dose of inhaled budesonide and formeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled budesonide and formeterol plus oral montelukast</intervention_name>
    <description>1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening</description>
    <arm_group_label>inhaled budesonide and formeterol plus oral montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled budesonide and formeterol plus oral doxophylline</intervention_name>
    <description>1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning</description>
    <arm_group_label>inhaled budesonide and formeterol plus oral doxophylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doubling the dose of inhaled budesonide and formeterol</intervention_name>
    <description>1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day</description>
    <arm_group_label>Doubling the dose of inhaled budesonide and formeterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 15 to 65 years of either sex

          -  had clinically diagnosed Bronchial asthma

          -  had poor asthma control defined by ACQ score (asthma control questionnaire) of 1.5 or
             greater

          -  FEV1 (Forced Expiratory Volume at 1 second) value of 50% or more of predicted

          -  improvement in FEV1 was greater than 15% after bronchodilator inhalation

        Exclusion Criteria:

          -  major illness of system other than respiratory major respiratory illness other than
             asthma taken long acting anti histaminic within a preceding week of enrollment Smokers
             Pregnant and lactating woman history of hypersensitivity to any of above drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Yogesh A Patel, M.B.B.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir T. General Hospital and Government Medical College, Bhavnagar-364001, Gujarat, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Chandrabhanu R Tripathi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor and Head, Department of Pharmacology, Government Medical College, Bhavnagar-364001, Gujarat, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Takthasinhji General Hospital Bhavnagar, Gujarat, India</name>
      <address>
        <city>Bhavnagar</city>
        <state>Gujarat</state>
        <zip>364001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>January 22, 2010</last_update_submitted>
  <last_update_submitted_qc>January 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. C. B. Tripathi, Professor and Head , Department of Pharmacology</name_title>
    <organization>Government Medical College, Bhavnagar-364001, Gujarat, India</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Doxofylline</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

